Heterocyclic Inhibitors of MEK and Methods of Use Thereof

Abstract

Disclosed are methods of treating hyperproliferative disorders, method of treating inflammatory disorders, and methods of inhibiting MEK activity in a mammal, comprising administering an effective amount of one or more compounds of the Formula V or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 7 , R 8 , R 9 and W are as defined in the specification.

1 . A method for treatment of a hyperproliferative or inflammatory disorder in a mammal, comprising administering to said mammal an effective amount of one or more compounds having the formula 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salts thereof, wherein
 R 1 , R 2 , and R 9  are independently hydrogen, halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —SR 11 , —OR 3 , —C(O)R 3 , —C(O)OR 3 , —NR 4 C(O)OR 6 , —OC(O)R 3 , —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 5 C(NCN)NR 3 R 4 , —NR 3 R 4 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, C 3 -C 10  cycloalkylalkyl, —S(O) j  (C 1 -C 6  alkyl), 
 —S(O) j (CR 4 R 5 ) m -aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, —O(CR 4 R 5 ) m -aryl, —NR 4 (CR 4 R 5 ) m -aryl, —O(CR 4 R 5 ) m -heteroaryl, —NR 4 (CR 4 R 5 ) m -heteroaryl, —O(CR 4 R 5 ) m -heterocyclyl or —NR 4 (CR 4 R 5 ) m -heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted independently with one or more groups independently selected from oxo (with the proviso that it is not substituted on an aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —C(O)R 3 , —C(O)OR 3 , —OC(O)R 3 , —NR 4 C(O)OR 6 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 5 C(NCN)NR 3 R 4 , 
 —OR 3 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, and wherein said aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl rings are optionally substituted independently with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 2 -C 4  alkynyl, C 3 -C 6  cycloalkyl, C 3 -C 6  heterocycloalkyl, NR 3 R 4  and OR 3 ; 
 R 7  is hydrogen, trifluoromethyl, C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, C 3 -C 10  cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted independently with one or more groups independently selected from oxo (with the proviso that it is not substituted on an aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)R 11 , —C(O)OR 11 , —OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 23 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, and wherein said aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl rings are optionally substituted independently with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 2 -C 4  alkynyl, C 3 -C 6  cycloalkyl, C 3 -C 6  heterocycloalkyl, NR 11 R 12  and OR 11 ; 
 R 8  is Br, I or SR 11 ; 
 R 3  is hydrogen, trifluoromethyl, C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, C 3 -C 10  cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted independently with one or more groups independently selected from oxo (with the proviso that it is not substituted on an aryl or heteroaryl), halogen, cyano, nitro, alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)R 11 , —C(O)OR 11 , —OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 12 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl heterocyclyl, and heterocyclylalkyl, 
 or R 3  and R 4  together with the atom to which they are attached form a 4 to 10 membered heteroaryl or heterocyclic ring, wherein said heteroaryl and heterocyclic rings are optionally substituted independently with one or more groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)R 11 , —C(O)R 11 , —C(O)OR 11 , —OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 12 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl; 
 R 4  and R 5  independently are hydrogen or C 1 -C 6  alkyl, or 
 R 4  and R 5  together with the atom to which they are attached form a 4 to 10 membered carbocyclic ring, wherein said alkyl and carbocyclic ring are optionally substituted independently with one or more groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)R 11 , —C(O)OR 11 , —OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 12 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkenyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl; 
 R 6  is trifluoromethyl, C 1 -C 10  alkyl, C 3 -C 10  cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted independently with one or more groups independently selected from oxo (with the proviso that it is not substituted on an aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)R 11 , —C(O)OR 11 , —OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 12 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; 
 R 11 , R 12  and R 13  independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, and R 14  is lower alkyl, lower alkenyl, aryl or arylalkyl, 
 or any two of R 11 , R 12 , R 13  and R 14  together with the atom to which they are attached form a 4 to 10 membered heteroaryl or heterocyclic ring, wherein said alkyl, alkenyl, aryl, arylalkyl, heteroaryl ring and heterocyclic ring are optionally substituted independently with one or more groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; 
 W is heteroaryl, heterocyclyl, —C(O)OR 3 , —C(O)NR 3 R 4 , —C(O)NR 4 OR 3 , —C(O)R 4 OR 3 , —C(O)NR 4 SO 2 R 3 , —C(O)(C 3 -C 10  cycloalkyl), —C(O)(C 1 -C 10  alkyl), —C(O)(heterocyclyl) or CR 3 R 4 OR 3 , wherein any of said cycloalkyl, alkyl, heteroaryl and heterocyclyl portions are optionally substituted independently with one or more groups independently selected from halogen, cyano, nitro, azido, —NR 3 R 4 , —OR 3 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, cycloalkyl and heterocycloalkyl, 
 provided that when W is C(O)OR 3  and R 9  is F, R 7  cannot be H; 
 m is 0, 1, 2, 3, 4 or 5; and 
 j is 0, 1 or 2. 
 
     
     
         2 . The method of  claim 1 , comprising administering a compound of Formula V wherein R 9  is hydrogen, halogen, cyano, amino, alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or anilino. 
     
     
         3 . The method of  claim 2 , comprising administering a compound of Formula V wherein W is selected from heteroaryl, —C(O)OR 3 , —C(O)NR 3 R 4 , —C(O)NR 4 OR 3  and —C(O)NR 4 S(O) 2 R 3 , wherein said heteroaryl is optionally substituted independently with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, amino, aminomethyl, dimethylamino, aminoethyl, diethylamino, ethoxy, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 2 -C 4  alkynyl, C 3 -C 6  cycloalkyl and C 3 -C 6  heterocycloalkyl. 
     
     
         4 . The method of  claim 2 , comprising administering a compound of Formula V wherein W is selected from —C(O)OR 3 , —C(O)NHR 3 , and —C(O)NHOR 3 , and R 3  is selected from hydrogen, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 2 -C 4  alkynyl, C 3 -C 6  cycloalkyl and C 3 -C 6  heterocycloalkyl, wherein any of said C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 2 -C 4  alkynyl, cycloalkyl or heterocycloalkyl are optionally substituted independently with one or more groups selected from —NR 11 R 12 , —OR 11 , alkyl and cycloalkyl. 
     
     
         5 . The method of  claim 3 , comprising administering a compound of Formula V wherein R 7  is C 1 -C 4  alkyl, C 2 -C 4  alkenyl or C 2 -C 4  alkynyl, wherein said C 1 -C 4  alkyl, C 2 -C 4  alkenyl and C 2 -C 4  alkynyl are optionally substituted independently with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy, amino, aminomethyl, dimethylamino, aminoethyl, diethylamino, ethoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl rings are optionally substituted independently with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 2 -C 4  alkynyl, C 3 -C 6  cycloalkyl, C 3 -C 6  heterocycloalkyl, —NR 11 R 12 , —OR 11 . 
     
     
         6 . The method of  claim 4 , comprising administering a compound of Formula V wherein R 7  is C 1 -C 4  alkyl, C 2 -C 4  alkenyl or C 2 -C 4  alkynyl, wherein said C 1 -C 4  alkyl, C 2 -C 4  alkenyl and C 2 -C 4  alkynyl are optionally substituted independently with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy, amino, aminomethyl, dimethylamino, aminoethyl, diethylamino, ethoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl rings are optionally substituted independently with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 2 -C 4  alkynyl, C 3 -C 6  cycloalkyl, C 3 -C 6  heterocycloalkyl, —NR 11 R 12 , and —OR 11 . 
     
     
         7 . The method of  claim 5 , comprising administering a compound of Formula V wherein R 1  and R 2  are independently hydrogen, halogen, methyl, fluoromethyl, difluoromethyl, trifluoromethyl or ethyl. 
     
     
         8 . The method of  claim 5 , comprising administering a compound of Formula V wherein R 1  is halogen or methyl and R 2  is hydrogen. 
     
     
         9 . The method of  claim 8 , comprising administering a compound of Formula V wherein R 9  is alkyl, halogen or CN. 
     
     
         10 . The method of  claim 9 , comprising administering a compound of Formula V wherein R 7  is methyl. 
     
     
         11 . The method of  claim 6 , comprising administering a compound of Formula V wherein R 1  and R 2  are independently hydrogen, halogen, methyl, fluoromethyl, difluoromethyl, trifluoromethyl or ethyl. 
     
     
         12 . The method of  claim 6 , comprising administering a compound of Formula V wherein R 1  is halogen or methyl and R 2  is hydrogen. 
     
     
         13 . The method of  claim 12 , comprising administering a compound of Formula V wherein R 9  of Formula V is alkyl, halogen or CN. 
     
     
         14 . The method of  claim 13 , comprising administering a compound of Formula V wherein R 7  is methyl. 
     
     
         15 . The method of  claim 1 , wherein said hyperproliferative disorder is cancer or a non-cancerous disorder. 
     
     
         16 . The method of  claim 15 , wherein said cancer is brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, esophageal, testicular, gynecological or thyroid cancer. 
     
     
         17 . The method of  claim 15 , wherein said non-cancerous disorder is benign hyperplasia of the skin, restenosis, or benign prostatic hypertrophy. 
     
     
         18 . The method of  claim 1 , wherein said disorder is an inflammatory disorder. 
     
     
         19 . A method of inhibiting MEK activity in a mammal comprising administrating to said mammal an effective amount of one or more compounds having the formula V: 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salts thereof, wherein
 R 1 , R 2 , and R 9  are independently hydrogen, halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —SR 11 , —OR 3 , —C(O)R 3 , —C(O)OR 3 , —NR 4 C(O)OR 6 , —OC(O)R 3 , —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 5 C(NCN)NR 3 R 4 , —NR 3 R 4 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, C 3 -C 10  cycloalkylalkyl, S(O) j  (C 1 -C 6  alkyl), 
 —S(O) j (CR 4 R 5 ) m -aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, —O(CR 4 R 5 ) m -aryl, —NR 4 (CR 4 R 5 ) m -aryl, —O(CR 4 R 5 ) m -heteroaryl, —NR 4 (CR 4 R 5 ) m -heteroaryl, —O(CR 4 R 5 ) m -heterocyclyl or —NR 4 (CR 4 R 5 ) m -heterocyclyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted independently with one or more groups independently selected from oxo (with the proviso that it is not substituted on an aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —C(O)R 3 , —C(O)OR 3 , —OC(O)R 3 , —NR 4 C(O)OR 6 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 5 C(NCN)NR 3 R 4 , 
 —OR 3 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl,aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, and wherein said aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl rings are optionally substituted independently with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 2 -C 4  alkynyl, C 3 -C 6  cycloalkyl, C 3 -C 6  heterocycloalkyl, NR 3 R 4  and OR 3 ; 
 R 7  is hydrogen, trifluoromethyl, C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, C 3 -C 10  cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted independently with one or more groups independently selected from oxo (with the proviso that it is not substituted on an aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)OR 11 , —OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 12 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, and wherein said aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl rings are optionally substituted independently with one or more groups selected from halogen, hydroxyl, cyano, nitro, azido, fluoromethyl, difluoromethyl, trifluoromethyl, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 2 -C 4  alkynyl, C 3 -C 6  cycloalkyl, C 3 -C 6  heterocycloalkyl, NR 11 R 12  and OR 11 ; 
 R 8  is Br, I or SR 11 ; 
 R 3  is hydrogen, trifluoromethyl, C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, C 3 -C 10  cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, phosphate or an amino acid residue, wherein any of said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted independently with one or more groups independently selected from oxo (with the proviso that it is not substituted on an aryl or heteroaryl), halogen, cyano, nitro, alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)R 11 , —C(O)OR 11 , OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 12 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl heterocyclyl, and heterocyclylalkyl, 
 or R 3  and R 4  together with the atom to which they are attached form a 4 to 10 membered heteroaryl or heterocyclic ring, wherein said heteroaryl and heterocyclic rings are optionally substituted independently with one or more groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)R 11 , —C(O)OR 11 , —OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 12 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl; 
 R 4  and R 5  independently are hydrogen or C 1 -C 6  alkyl, or 
 R 4  and R 5  together with the atom to which they are attached form a 4 to 10 membered carbocyclic ring, wherein said alkyl and carbocyclic ring are optionally substituted independently with one or more groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)R 11 , —C(O)OR 11 , —OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 12 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl; 
 R 6  is trifluoromethyl, C 1 -C 10  alkyl, C 3 -C 10  cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein said alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl portions are optionally substituted independently with one or more groups independently selected from oxo (with the proviso that it is not substituted on an aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 11 SO 2 R 14 , —SO 2 NR 11 R 12 , —C(O)R 11 , —C(O)OR 11 , —OC(O)R 11 , —NR 11 C(O)OR 14 , —NR 11 C(O)R 12 , —C(O)NR 11 R 12 , —SR 11 , —S(O)R 14 , —SO 2 R 14 , —NR 11 R 12 , —NR 11 C(O)NR 12 R 13 , —NR 11 C(NCN)NR 12 R 13 , —OR 11 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; 
 R 11 , R 12  and R 13  independently are hydrogen, lower alkyl, lower alkenyl, aryl or arylalkyl, and R 14  is lower alkyl, lower alkenyl, aryl or arylalkyl, 
 or any two of R 11 , R 12 , R 13  and R 14  together with the atom to which they are attached form a 4 to 10 membered heteroaryl or heterocyclic ring, wherein said alkyl, alkenyl, aryl, arylalkyl, heteroaryl ring and heterocyclic ring are optionally substituted independently with one or more groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, C 3 -C 10  cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; 
 W is heteroaryl, heterocyclyl, —C(O)OR 3 , —C(O)NR 3 R 4 , —C(O)NR 4 OR 3 , —C(O)R 4 OR 3 , —C(O)NR 4 SO 2 R 3 , —C(O)(C 3 -C 10  cycloalkyl), —C(O)(C 1 -C 10  alkyl), —C(O)(heterocyclyl) or CR 3 R 4 OR 3 , wherein any of said cycloalkyl, alkyl, heteroaryl and heterocyclyl portions are optionally substituted independently with one or more groups independently selected from halogen, cyano, nitro, azido, —NR 3 R 4 , —OR 3 , C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, cycloalkyl and heterocycloalkyl, 
 provided that when W is C(O)OR 3  and R 9  is F, R 7  cannot be H; 
 m is 0, 1, 2, 3, 4 or 5; and 
 j is 0, 1 or 2.